December 8, 2005
Humanetics and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Sign Exclusive License for Oral Agent to Protect and Stregthen the Immune System Against Radiation Exposure in Terrorist Attack
MINNEAPOLIS, MN, December 8, 2005-- Humanetics Corporation today announced the signing of a worldwide exclusive licensing agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., (HJF) to further develop an oral agent, BIO300, for strengthening and protecting the immune system against radiation exposure.
BIO300 was jointly developed by researchers at the Armed Forces Radiobiology Research Institute (AFRRI) and the National Institutes of Health (NIH). AFRRI, in Bethesda, Maryland, is part of the Uniformed Services University of the Health Sciences (USU), a Congressionally-chartered, fully-accredited, graduate education university operated by the Department of Defense. HJF, in Rockville, Maryland, is a private, not-for-profit organization chartered by Congress to support medical education and research at USU and throughout the military medical community.
BIO300 has been shown in animal models to be highly effective in protecting the immune system against harm caused by exposure to whole-body ionizing radiation. Under the exclusive license, Humanetics will assume responsibility for continued testing, development and commercialization of BIO300. A Cooperative Research and Development Agreement (CRADA), has been entered into with USU and HJF for Humanetics to collaborate with AFRRI, the nation’s premier center for radiation injury countermeasure research, and with the F. Edward Hébert School of Medicine, to test and develop BIO300. Humanetics intends to develop and commercialize BIO300 as an oral countermeasure to support and protect the immune system against challenges from exposure to ionizing radiation resulting from a terrorist attack or nuclear accident.
Humanetics and AFRRI are pursuing a number of oral countermeasures, all of which have been shown to be effective in increasing survival in mice receiving otherwise lethal doses of radiation. Based on animal screening models, BIO300 has emerged as the leading candidate for commercialization.
Humanetics believes that as a result of the level of chaos likely following a catastrophic event such as a radiation accident or nuclear terrorist attack, civilians may have to rely solely on products in their possession before the catastrophe. There are an estimated 90 million civilians in the 10 metropolitan areas in the United States considered at greatest risk from a terrorist attack. By developing oral countermeasures, Humanetics is pursuing the ability to provide products that may be distributed in advance of an event and will offer a level of protection presently unavailable to the American public.
“We are proud to have licensed this important oral agent developed at USU/AFRRI and the NIH, and look forward to further development in collaboration with AFRRI leading to final testing and commercialization of BIO300,” says Ronald Zenk, President and CEO of Humanetics. “Their discoveries provide a substantial platform from which we intend to develop a safe and effective oral countermeasure in the event of a radiation accident or radiological/nuclear terrorist attack.”